Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
The planned initial study would evaluate safety and drug processing in humans, but regulatory and ethics approvals remain pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marvel Biosciences (MBCOF) has selected CMAX in Adelaide, Australia, as the Phase I clinical site for first-in-human testing of MB-204.
Marvel plans to begin with a single ascending dose study, testing progressively higher doses to evaluate safety, tolerability and how the drug moves through the body. The study is also expected to assess potential biomarkers and selected cognitive endpoints to inform a later multiple ascending dose study. Initiation remains subject to regulatory and ethics approvals and completion of clinical preparations.
Preclinical work reported behavioural and cognitive improvements in Rett, Fragile X and autism mouse models. The August 2026 Fragile X study showed statistically significant recognition-memory improvements at both tested doses, with persistent effects on selected endpoints after treatment ended. Preliminary Shank3 mouse findings showed behavioural improvements; final analyses and additional endpoints remained pending.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCMAX selected as the Phase I site for MB-204 first-in-human testing in Adelaide, Australia.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned single ascending dose study will evaluate initial human safety, tolerability and drug processing.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential biomarkers and selected cognitive endpoints are expected to inform a subsequent multiple ascending dose study.
- Minor pointRett and autism mouse models showed behavioural and cognitive improvements with MB-204.
- Minor pointAugust 2026 Fragile X study showed statistically significant recognition-memory improvements at both tested doses.
2 minor points
- Minor pointSelected Fragile X endpoints showed persistent effects after treatment cessation.
- Minor pointPreliminary Shank3 mouse findings indicated improvements across multiple behavioural measures.
Negative
- Moderate pointTrial initiation remains subject to regulatory and ethics approvals and completion of clinical preparations.
- Minor pointShank3 final statistical analyses and additional endpoints remained pending at the time of the preliminary announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the Phase I clinical site to test its lead drug candidate MB-204, an important step in the Company’s preparations to advance its lead patented drug candidate toward first-in-human clinical evaluation.
CMAX Clinical Research is an independent clinical research facility, based in Adelaide, Australia. CMAX has been established as a Phase I unit since December 1993, making it the longest-running in Australia and, since establishment, has consistently maintained world class standards with a total commitment to providing excellence and quality in all areas of clinical service. CMAX is also one of Australia’s most modern Phase I clinical facilities, adjacent to Adelaide’s Biomed City. The facility offers 78‐bed capacity for in‐house stays and conducts >40 studies per year. The CMAX site specialises in Phase I – FTIH, SAD/MAD, first time in patients, BA/BE, PK/PD and Proof-Of-Concept studies. CMAX has conducted >600 studies since the unit was established.
Marvel’s preparations for clinical development are supported by a growing body of preclinical research evaluating MB-204 across multiple genetically distinct models of neurodevelopmental disorders. The Company has reported behavioural and cognitive improvements in mouse models associated with Rett syndrome (Mecp2), Fragile X syndrome (Fmr1) and autism spectrum disorder (Oprm1), alongside preliminary findings from a Shank3 mouse model associated with Phelan-McDermid syndrome. In its August 2026 Fragile X study, Marvel reported statistically significant improvements in recognition memory at both tested doses and persistent effects on selected endpoints following treatment cessation (refer to press release dated August 5, 2026). Preliminary Shank3 findings also indicated improvements across multiple behavioural measures, although final statistical analyses and additional endpoints remained pending at the time of that announcement (refer to press release dated October 8, 2026).
“We are pleased to be working with CMAX and Novotech as our clinical partners for the Phase I trial of MB-204”, commented Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. “We look forward to navigating the ethics approval and regulatory process with both groups to start clinical testing.”
The selection of CMAX represents an important operational step in Marvel’s preparations to advance MB-204 toward first-in-human clinical evaluation. As previously disclosed, the Company is planning a Phase I program beginning with a single ascending dose (SAD) study designed to evaluate the candidate’s initial safety, tolerability and pharmacokinetic profile in humans. The planned study is also expected to assess potential biomarkers and selected cognitive endpoints, with findings intended to inform the design of a subsequent multiple ascending dose (MAD) study. Initiation of the trial remains subject to applicable regulatory and ethics approvals and completion of the necessary clinical preparations.
About Marvel Biosciences Corp.
Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Where will Marvel Biosciences conduct the MB-204 Phase I trial?
Marvel selected CMAX in Adelaide, Australia, as the Phase I clinical site for MB-204. Trial initiation remains subject to applicable regulatory and ethics approvals and completion of the necessary clinical preparations.
What will Marvel Biosciences test in the initial MB-204 human study?
The planned single ascending dose study will evaluate initial safety, tolerability and how MB-204 moves through the human body. It is also expected to assess potential biomarkers and selected cognitive endpoints, with findings intended to inform a subsequent multiple ascending dose study.